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ABSTRACT
Drug-induced pseudolymphoma syndrome is a rare form of adverse cutaneous drug 
reaction. Its clinical and histological presentation may mimic mycosis fungoides, which 
sometimes leads to misdiagnosis and unnecessary treatments. We describe the case of 
a 65-year-old man with a generalized pruritic and confluent maculopapular eruption. 
His history of skin lesions was concordant with medication and resolved after discon-
tinuation. However, microscopic examination showed characteristic features of myco-
sis fungoides, including Pautrier-like microabscesses and cerebriform nuclei of atypical 
lymphocytes. The immunohistochemical study showed CD4/CD8 infiltrate ratio to be 1 
in the epidermis. The histopathological result of a second skin biopsy was compatible 
with drug eruption. This experience demonstrates that combining clinical history, histo-
logical and immunohistochemical findings is crucial for a definite diagnosis of PLS.
Copyright © 2010, Taiwanese Dermatological Association. 






Pseudolymphoma syndrome (PLS) was first reported by 
Chaiken et al in 1950.1 PLS is a rare form of adverse cuta-
neous drug reaction with clinicopathological features similar 
to that of mycosis fungoides. In the literature, antiepileptic 
agents are the most frequently cited offending medications for 
PLS.2 In this report, we presented a case of naproxen-induced 
PLS that histologically mimics mycosis fungoides.
Case report
A 65-year-old man, a sufferer of benign prostate hyperpla-
sia and diabetes mellitus type 2, received regular medical 
attention (tamsulosin HCl, tolterodine for benign prostate 
hyperplasia, acarbose, glimepiride for diabetes mellitus 
more than 1 year) in a tertiary medical center in Central 
Taiwan. Due to an episode of fever, nausea, vomiting and 
persistent epigastralgia, he was admitted to the hospital. 
Empiric antibiotics with intravenous cefazolin and gen-
tamicin, medication for benign prostate hyperplasia and 
diabetes mellitus, as well as acetaminophen and metoclo-
pramide were prescribed. During hospitalization, abdominal 
computed tomography with contrast enhancement showed 
pancreatic cancer and surgical excision was recommended. 
But the patient was discharged against medical advice.
After discharge, naproxen, levofloxacin and drugs for be-
nign prostate hyperplasia and diabetes mellitus were pre-
scribed. Three days after discharge, he had a fever (up to 
39°C) and itchy skin rashes covering the whole body except 
the palms and soles (Figure 1). Physical examination revealed 
confluent maculopapular eruptions with pruritus on the trunk 
and all four limbs, but no enlarged lymph nodes. Laboratory 
investigations revealed leukocytosis (13.9 ˜  109/L), eosi-
nophilia (1.0 ˜  109/L), and atypical lymphocytes (0.3 ˜  109/L). 
Liver function tests showed a mildly elevated aspartate 
aminotransferase level (1.0 μkat/L), and increased alkaline 
phosphatase (3.9 μkat/L). Naproxen was discontinued and 
prednisolone (10 mg bid) was prescribed.
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Results from skin biopsy of the forearm showed Pautrier-
like microabscesses in the epidermis. Using a high power 
field, mononuclear infiltrates with cerebriform nuclei were 
easily identified in the lymphocytic infiltrates. Focal vacuolar 
change of basal keratinocytes without necrotic keratino-
cytes was also observed (Figure 2). The above features were 
suggestive of mycosis fungoides. Immunohistochemical anal-
ysis of the infiltrate revealed most of the medium-sized 
atypical lymphocytes were CD3 positive, and a mixture of 
CD4 and CD8 cells was observed in the epidermis (Figure 3). 
The cutaneous lesions resolved with residual erythema after 
1 week of oral prednisolone (Figure 4). A second skin 
biopsy was then performed to exclude mycosis fungoides. 
Histological findings showed a few necrotic cells in the 
basal layer and an infiltrate in the upper dermis. This infiltrate 
was composed of lymphohistiocytes and some eosinophils. 
No epidermotropism or atypical lymphoid cells were found 
in the upper dermis (Figure 5). Thus a definite diagnosis of 
drug eruption was made, and naproxen was identified as the 
offending drug. The steroid was discontinued after 2 weeks 
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Figure 2 Skin biopsy of the right forearm. (A) Lymphocytic infiltration in the epidermis and band-like infiltration in superficial dermis (H&E, 40˜). 
(B,C) Extensive Pautrier-like microabscesses in the epidermis (H&E, 200˜ , 400˜). (D) Cerebriform nuclei of medium-sized atypical lymphocytes 
in the upper dermis (H&E, 400˜).
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Figure 1 Generalized maculopapular eruptions (A) on the trunk and (B,C) all four limbs.
Naproxen-induced pseudolymphoma syndrome 29
A B
C D
Figure 3 Immunohistochemical staining showing (A) CD3 positive lymphocytes, (B) CD20 negative lymphocytes, (C) CD4 positive lymphocytes, 
(D) CD8 positive lymphocytes in the epidermis and dermis (CD3, CD20, CD4 and CD8 respectively, all at 100˜).
B CA
Figure 4 Cutaneous rash (A) on the trunk and (B,C) four limbs almost resolved except for residual erythema on the thigh.
A B C
Figure 5 Skin biopsy of the left thigh. (A) Parakeratosis and mild infiltration in superficial dermis (H&E, 40˜). (B) Few dyskerototic cells in the 
basal layer of epidermis (H&E, 200˜). (C) Lymphohistiocytes and some eosinphils in upper dermis (H&E, 400˜).
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of treatment. No recurrence of symptoms occurred in the 
3-month follow-up period.
Discussion
Drug eruptions mimicking mycosis fungoides clinically or 
histologically are rare. Such disorders were first described 
after the introduction of hydantoin and its derivatives for 
the treatment of convulsive disorders in the early 1940s.3 
Historically, the term drug-induced pseudolymphoma is 
used to describe two kinds of adverse drug eruptions.4 The 
first is an adverse drug eruption histologically mimicking a 
cutaneous lymphoma, which was then referred to as PLS. 
The second is a hypersensitivity syndrome which presents 
fever, cutaneous eruption, lymphadenopathy, eosinophilia, 
and hepatosplenomegaly, known as drug rash with eosi-
nophilia and systemic symptoms. Bocquet et al4 differenti-
ated PLS from drug rash with eosinophilia and systemic 
symptoms based on clinical presentation, and suggested 
limiting PLS to cases with slow onset plaques or tumors. 
However, because these two entities may not only exhibit 
similar histological findings but also overlapping clinical 
features, the nosological characteristics of these drug erup-
tions remain unresolved.
The pathogenesis of PLS is not understood, and it maybe 
a multifactorial process. The offending drugs perturb lym-
phoid function in vitro and may promote blast transforma-
tion and impair T-cell suppressor function to induce an 
exaggerated lymphocyte response to exogenous antigenic 
triggers.5 This may be exhibited as a drug-induced dysregu-
lated immune reaction to the drug itself, to some other 
drugs, or to a non-pharmacological antigen.6 This theory 
is supported by in vivo evidence of disturbance of the 
immune system by the offending drugs.6
Clinically, the 3 major symptoms of PLS are fever (up to 
38–39°C), lymphadenopathy and skin rash. The manifesta-
tions of lymphadenopathy may or may not be present and 
histological examination of the lymph nodes may reveal 
either a benign lymphoid hyperplasia or a pseudolymphoma 
pattern.4,7 Skin rash may include a morbilliform maculopa-
pular eruption with pruritus in the extremities, including 
the palm and sole, face and trunk, and less commonly, per-
ifollicular papules or generalized pustular lesion.8 Other 
associated symptoms include facial edema, hepatospleno-
megaly, vomiting, headache, arthralgia, pharyngitis and con-
junctivitis. The majority of patients suffer only mild hepatic 
injury and recover within a few weeks of the cessation of 
the causative agent. However, when hepatitis is severe, the 
prognosis is often poor. One study9 reported a mortality 
rate of 10–50%. Furthermore, hematological abnormalities 
are common in PLS, including leukocytosis, eosinophilia, and 
atypical lymphocytes, at times with lymphocytosis, monocy-
tosis, aplastic anemia, hyper- and hypo-gammaglobulinemia, 
coagulation disorder and nephritis.10,11 PLS usually devel-
ops within 3 months of using the causative drug, although 
it may also develop 1 week to 2 years after exposure to the 
drug, or sooner at rechallenge.4 Implicated drugs include 
phenytoin, carbamazepine, sodium valproate, gemcitabine, 
gold, the clonidine patch and Gleevec.12,13
Histologically, a band-like infiltrate with cerebriform nu-
clei in the dermis and possible Pautrier-like microabscesses 
in the epidermis often make PLS indistinguishable from 
mycosis fungoides.8 In 2003, Choi et al8 proposed a number 
of histological features that might be used to identify PLS, 
including more obvious spongiosis and papillary edema, 
more necrotic keratinocytes, mitosis, mixed inflammatory 
cell infiltrates and denser cellular infiltration in the dermis 
than in the epidermis. Immunohistochemically, the 1 to 1 
CD4/CD8 infiltrate ratio was consistent with the reactive 
process, and therefore allowed for diagnosis of PLS.13 While 
the clinicopathological and molecular features might make 
it difficult to differentiate PLS from mycosis fungoides, resolu-
tion after drug withdrawal is the diagnostic gold standard.14
In the case we presented, mycosis fungoides is strongly 
histologically favored due to the presence of Pautrier-like 
microabscesses and cerebriform nuclei of lymphoid cells 
without necrotic keratinocytes or papillary edema in the 
biopsy specimen. However, after drug withdrawal, the 
skin lesions resolved, which facilitated a diagnosis of PLS. 
The second skin biopsy results further confirmed the diag-
nosis. Magro and Crowson6 proposed that non-steroidal 
anti-inflammatory drugs may perturb lymphocyte function 
and induce cutaneous pseudolymphoma. Based on the 
clinical history, the diagnosis of naproxen-induced PLS was 
established.
The most important therapeutic step is the discontinuation 
of the offending drug. Although systemic steroids are widely 
used in the acute phase of disease, it is unclear whether 
steroids can significantly alter the disease process.15,16 
Symptomatic therapies for fever with antipyretics should be 
prescribed carefully to avoid aggravating liver toxicity. 
Topical steroids and antihistamines could be prescribed for 
cutaneous rash and pruritus. 
In conclusion, we reported a case of naproxen-induced 
PLS, histologically mimicking mycosis fungoides. The diag-
nosis was established based on the clearing of the skin le-
sions upon discontinuation of the offending drug. A second 
skin biopsy confirmed the benign nature of the lesions. This 
experience demonstrates that combining clinical history, 
histological and immunological findings is crucial for a 
definite diagnosis of PLS. 
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